Sec Form 4 Filing - Malin Life Sciences Holdings Ltd @ Poseida Therapeutics, Inc. - 2020-07-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Malin Life Sciences Holdings Ltd 2. Issuer Name and Ticker or Trading Symbol Poseida Therapeutics, Inc. [ PSTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) THE LENNOX BUILDING, 50 RICHMOND STREET SOUTH 3. Date of Earliest Transaction (MM/DD/YY) 07/14/2020 (Street) DUBLIN, L2D02 FK02 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/14/2020 C 7,013,918 A 7,013,918 D ( 2 ) Common Stock 07/14/2020 C 1,168,985 A 8,182,903 D ( 2 ) Common Stock 07/14/2020 C 690,124 A 8,873,027 D ( 2 ) Common Stock 07/14/2020 C 315,098 A 9,188,125 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 07/14/2020 C 8,746,356 ( 1 ) ( 1 ) Common Stock 7,013,918 ( 1 ) 0 D ( 2 ) Series A-1 Preferred Stock ( 1 ) 07/14/2020 C 1,457,725 ( 1 ) ( 1 ) Common Stock 1,168,985 ( 1 ) 0 D ( 2 ) Series B Preferred Stock ( 1 ) 07/14/2020 C 860,585 ( 1 ) ( 1 ) Common Stock 690,124 ( 1 ) 0 D ( 2 ) Series C Preferred Stock ( 1 ) 07/14/2020 C 392,927 ( 1 ) ( 1 ) Common Stock 315,098 ( 1 ) 0 D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Malin Life Sciences Holdings Ltd THE LENNOX BUILDING 50 RICHMOND STREET SOUTH DUBLIN, L2D02 FK02 X Malin Corp plc THE LENNOX BUILDING 50 RICHMOND STREET SOUTH DUBLIN, L2D02 FK02 X Signatures Malin Life Sciences Holdings Ltd, By: /s/ Michael A. Goldstein, Esq., Attorney-in-Fact 07/15/2020 Signature of Reporting Person Date Malin Corporation plc, By: /s/ Michael A. Goldstein, Esq., Attorney-in-Fact 07/15/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )All shares of preferred stock, $0.0001 par value per share, of the Issuer, (i) had no expiration date and (ii) automatically converted into the Issuer's common stock, $0.0001 par value per share, on a 1-for-0.8019246 basis immediately prior to the closing of the Issuer's initial public offering. ( 2 )Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.

Remarks: (1) Exhibit 24 - Power of Attorney (incorporated by reference to Power of Attorney filed as Exhibit 24 to the Form 3 filed by the Reporting Persons on July 9, 2020) (2) Exhibit 99.1 - Joint Filer Information

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.